Remove Article Remove Immune Response Remove Virus
article thumbnail

Can Global Genomic Surveillance Forecast the Next Pandemic?

PLOS: DNA Science

A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. Did it there either recombine with another virus on its own, or inspire a manipulation of another virus of a key part of the spike gene, seeding the pandemic through a “lab leak?” Work on vaccines ensued too.

Virus 98
article thumbnail

Not all neoantigens are created equal

Drug Target Review

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Recognition of bacteria, viruses and fungal invaders as ‘foreign’ makes sense, but how does the immune system recognise cancer cells as a threat?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scaling Phage Therapy

Codon

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 131
article thumbnail

Article FDA Thank You Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines

Agency IQ

BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.

Vaccine 40
article thumbnail

Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

The Pharma Data

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. 4,5 Efficacy varied by serotype.

Vaccine 52
article thumbnail

The Altascientist Issue 36: Navigating the Key Considerations of Your Nonclinical Cell and Gene Therapy Studies

Alta Sciences

The in vivo nonclinical study of cell and gene therapies includes a thorough understanding of on-and-off-target activity, immune responses, and other adverse events just to name a few. There are three primary vectors employed in gene therapy: adeno-associated virus (AAV), adenovirus, or lentivirus vectors. Weight 15

article thumbnail

New insights into the role of viral capsids in gene therapy safety

Drug Target Review

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.